Shunde Wang
Overview
Explore the profile of Shunde Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
15
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang S, Zheng B, Yang J, Zhang J
Curr Cancer Drug Targets
. 2025 Mar;
PMID: 40051366
Background: Historically, there has been a lack of focus on the mortality rates of individuals with both diabetes and Bladder Bancer (BC). Our study aimed to identify the risk factors...
2.
He J, Wang S, Liu H, Duan C, Zhang H, Wen F, et al.
Transl Cancer Res
. 2024 Jan;
12(12):3591-3603.
PMID: 38192997
Background: Cardiovascular disease (CVD) is the leading cause of death for all non-cancer deaths among breast cancer (BC) patients. The aim of this study was to investigate the risk of...
3.
Wang S, Ge C
Urol J
. 2023 Sep;
21(3):146-154.
PMID: 37727915
Purpose: This study was designed to evaluate risk of mortality from chronic obstructive pulmonary disease (COPD) in patients with bladder cancer (BC). Methods And Materials: Data on patients diagnosed with...
4.
Wang S, Yuan X, Shen Z, Zhao J, Zheng B, Zhang J, et al.
Investig Clin Urol
. 2023 Jun;
64(3):229-241.
PMID: 37341003
To systematically evaluate the differences in therapeutic response to chemotherapy or immunotherapy between different molecular subtypes of bladder cancer (BC). A comprehensive literature search was performed up to December 2021....
5.
Wang S, Ge C
J Cancer Res Clin Oncol
. 2023 Jun;
149(12):10203-10215.
PMID: 37270459
Purpose: The objective of this study was to investigate non-cancer causes of death and associated risk factors after bladder cancer (BC) diagnosis. Methods: Eligible BC patients were obtained from the...
6.
Zheng B, Wang S, Yuan X, Zhang J, Shen Z, Ge C
BMC Urol
. 2023 May;
23(1):82.
PMID: 37138262
Background: Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies. Recently, immunotherapy has been considered a promising treatment for metastatic ccRCC. NUF2 is a crucial component...
7.
Wang S, Ge C, Zhang J
J Cardiovasc Dev Dis
. 2022 Aug;
9(8).
PMID: 36005419
Background: The purpose of this study was to evaluate the risk of cardiovascular mortality (CVM) among patients with bladder cancer (BC). Methods And Materials: Data were collected from the Surveillance,...
8.
He J, Sun H, Li F, Yang H, Lou M, Wang S, et al.
Hepatol Res
. 2021 Sep;
51(11):1153-1163.
PMID: 34492152
Aim: This study aimed to evaluate efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization (TACE) for intermediate and advanced hepatocellular carcinoma (HCC) using real-world evidence. Methods: All eligible HCC cases...
9.
Wang S, Wang S, Li H, Li X, Xie M, Wen J, et al.
Exp Ther Med
. 2018 May;
15(6):5269-5274.
PMID: 29805545
The molecular mechanism of the aromatase inhibitor letrozole was investigated. It promotes the proliferation of spermatogonia by regulating the mitogen-activated protein kinase (MAPK) pathway. Six different concentrations were selected for...